Cardiac hypertrophy by hypertension and exercise training exhibits different gene expression of enzymes in energy metabolism - PubMed (original) (raw)
. 2003 Oct;26(10):829-37.
doi: 10.1291/hypres.26.829.
Affiliations
- PMID: 14621187
- DOI: 10.1291/hypres.26.829
Free article
Cardiac hypertrophy by hypertension and exercise training exhibits different gene expression of enzymes in energy metabolism
Motoyuki Iemitsu et al. Hypertens Res. 2003 Oct.
Free article
Abstract
Hypertension-induced pathological cardiac hypertrophy (hypertensive heart) and exercise training-induced physiological cardiac hypertrophy (athletic heart) have differences in cardiac properties. We hypothesized that gene expression of energy metabolic enzymes differs between these two types of cardiac hypertrophy. To investigate whether mRNA expression of key enzymes in the long-chain fatty acid (FA), glucose, and lactic acid metabolic pathways differs between these two types of cardiac hypertrophy, we used the hearts of spontaneously hypertensive rats (SHR; 19 weeks old) as a model of the hypertensive heart, swim-trained rats (Trained; 19 weeks old, swimming training for 15 weeks) as a model of the athletic heart, and sedentary Wistar-Kyoto rats (Control; 19 weeks old). SHR developed hypertensive cardiac hypertrophy, of which cardiac function was deteriorated, whereas Trained rats developed an athletic heart, of which cardiac function was enhanced. The mRNA expression of CD36, which involved in uptake of long-chain FA, in the heart was almost never detected in the SHR group. Furthermore, the mRNA expression of key enzymes in the long-chain FA metabolic pathway (acyl CoA synthase [ACoAS], carnitine palmitoyl transferase [CPT]-I, CPT-II, and isocitrate dehydrogenase [ISCD]) in the heart was significantly higher in the SHR group compared with the Control group. The mRNA expression of ACoAS, CPT-I, ISCD, and CD36 in the heart did not differ between Trained group and Control group, whereas that of CPT-II in the Trained group was significantly higher compared with the Control group. The mRNA expression of key enzymes (phosphofructokinase and lactate dehydrogenase) in glycolytic metabolic pathway in the heart was markedly higher in the SHR group compared with the Control group, whereas these mRNA expressions did not differ between Trained group and Control group. These findings suggest that the molecular phenotypes in the energy metabolic system differ in hypertension-induced pathological and exercise training-induced physiological cardiac hypertrophy, and these differences may participate in the differences in cardiac function.
Similar articles
- Physiological and pathological cardiac hypertrophy induce different molecular phenotypes in the rat.
Iemitsu M, Miyauchi T, Maeda S, Sakai S, Kobayashi T, Fujii N, Miyazaki H, Matsuda M, Yamaguchi I. Iemitsu M, et al. Am J Physiol Regul Integr Comp Physiol. 2001 Dec;281(6):R2029-36. doi: 10.1152/ajpregu.2001.281.6.R2029. Am J Physiol Regul Integr Comp Physiol. 2001. PMID: 11705790 - The benefit of medium-chain triglyceride therapy on the cardiac function of SHRs is associated with a reversal of metabolic and signaling alterations.
Iemitsu M, Shimojo N, Maeda S, Irukayama-Tomobe Y, Sakai S, Ohkubo T, Tanaka Y, Miyauchi T. Iemitsu M, et al. Am J Physiol Heart Circ Physiol. 2008 Jul;295(1):H136-44. doi: 10.1152/ajpheart.01417.2006. Epub 2008 May 2. Am J Physiol Heart Circ Physiol. 2008. PMID: 18456726 - Effects of medium-chain triglyceride (MCT) application to SHR on cardiac function, hypertrophy and expression of endothelin-1 mRNA and other genes.
Shimojo N, Miyauchi T, Iemitsu M, Irukayama-Tomobe Y, Maeda S, Ohkubo T, Tanaka Y, Goto K, Yamaguchi I. Shimojo N, et al. J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S181-5. doi: 10.1097/01.fjc.0000166263.19852.fc. J Cardiovasc Pharmacol. 2004. PMID: 15838274 - Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies.
Bernardo BC, Weeks KL, Pretorius L, McMullen JR. Bernardo BC, et al. Pharmacol Ther. 2010 Oct;128(1):191-227. doi: 10.1016/j.pharmthera.2010.04.005. Epub 2010 May 12. Pharmacol Ther. 2010. PMID: 20438756 Review. - Beneficial Effects of Exercise on Hypertension-Induced Cardiac Hypertrophy in Adolescents and Young Adults.
Tsuda T, Robinson BW. Tsuda T, et al. Curr Hypertens Rep. 2024 Nov;26(11):451-462. doi: 10.1007/s11906-024-01313-4. Epub 2024 Jun 18. Curr Hypertens Rep. 2024. PMID: 38888690 Review.
Cited by
- Variation in tissue-specific gene expression among natural populations.
Whitehead A, Crawford DL. Whitehead A, et al. Genome Biol. 2005;6(2):R13. doi: 10.1186/gb-2005-6-2-r13. Epub 2005 Jan 26. Genome Biol. 2005. PMID: 15693942 Free PMC article. - An "Exercise" in Cardiac Metabolism.
Kolwicz SC Jr. Kolwicz SC Jr. Front Cardiovasc Med. 2018 Jun 7;5:66. doi: 10.3389/fcvm.2018.00066. eCollection 2018. Front Cardiovasc Med. 2018. PMID: 29930946 Free PMC article. Review. - Mitochondrial dysfunction in heart failure.
Rosca MG, Hoppel CL. Rosca MG, et al. Heart Fail Rev. 2013 Sep;18(5):607-22. doi: 10.1007/s10741-012-9340-0. Heart Fail Rev. 2013. PMID: 22948484 Free PMC article. Review. - Substrate uptake and metabolism are preserved in hypertrophic caveolin-3 knockout hearts.
Augustus AS, Buchanan J, Addya S, Rengo G, Pestell RG, Fortina P, Koch WJ, Bensadoun A, Abel ED, Lisanti MP. Augustus AS, et al. Am J Physiol Heart Circ Physiol. 2008 Aug;295(2):H657-66. doi: 10.1152/ajpheart.00387.2008. Epub 2008 Jun 13. Am J Physiol Heart Circ Physiol. 2008. PMID: 18552160 Free PMC article. - Mitochondria in cardiac hypertrophy and heart failure.
Rosca MG, Tandler B, Hoppel CL. Rosca MG, et al. J Mol Cell Cardiol. 2013 Feb;55:31-41. doi: 10.1016/j.yjmcc.2012.09.002. Epub 2012 Sep 13. J Mol Cell Cardiol. 2013. PMID: 22982369 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical